128 Medication non-adherence assessed using liquid chromatography tandem mass spectrometry in patients with chronic heart failure

BackgroundReported rates of medication non-adherence in patients with chronic heart failure (CHF) vary widely, depending on the method of assessment. Very few studies have assessed non-adherence objectively by evaluating the plasma level of medications or metabolites. The actual prevalence of medica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart (British Cardiac Society) 2023-06, Vol.109 (Suppl 3), p.A145-A146
Hauptverfasser: Sze, Shirley, Squire, Iain, Gupta, Pankaj, Krishnan, Sunanthiny, Lane, Dan, Clark, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundReported rates of medication non-adherence in patients with chronic heart failure (CHF) vary widely, depending on the method of assessment. Very few studies have assessed non-adherence objectively by evaluating the plasma level of medications or metabolites. The actual prevalence of medication non-adherence in CHF patients is currently unknown.ObjectivesTo evaluate the prevalence and clinical associates of medication non-adherence in a cohort of patients with CHF assessed using liquid chromatography–tandem mass spectrometry analysis of plasma levels of prescribed, evidence-based treatments.MethodsMedication adherence was evaluated in consecutive patients with CHF attending a routine clinic follow-up visit. Liquid chromatography-tandem mass spectrometry was used to measure the presence of prescribed medications (angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blocker (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), diuretics and digoxin) in plasma samples collected during the visit. None of the patients knew in advance that the blood test would be used to assess adherence.ResultsOf the 172 CHF patients studied, 69% were male; median (IQR) age was 76 (67-82) years; median NTproBNP was 1036 (433-2340) ng/L; 62% had HF with reduced ejection fraction (HFrEF, LVEF
ISSN:1355-6037
1468-201X
DOI:10.1136/heartjnl-2023-BCS.128